SEKISUI CHEMICAL CO., LTD.



For 2Q FY2024, ending March 31, 2025 **Presentation of Financial Results Progress under Management Plan**

Keita Kato

President and CEO

October 31, 2024

Main Points of Today's Presentation

SEKISUI

									★ : Record ł	nigh
(JPY bill	lion)	1H FY2024 Results	Compared with 1H FY2023 Results	Difference from Forecasts (July 2024)	2H FY2024 Revised Plan	Compared with 2H FY2023 Results	Difference from Forecasts (July 2024)	FY2024 Revised Plan	Compared with FY2023 Results	Difference from Forecasts (July 2024)
Net sales		★629.1	+17.8	-6.6	★679.6	+34.4	-11.4	★ 1,308.7	+52.2	-18.0
Operating prof	fit	★48.7	+7.6	+3.9	★56.3	+3.0	-0.9	★105.0	+10.6	+3.0
Ordinary profi	it	48.1	-3.4	+1.8	★54.4	0	-1.8	102.5	-3.4	0
Profit attributat		42.9	-1.5	+3.4	35.1	+1.6	-3.4	★78.0	+0.1	0
Dividend per sh (JPY)	are	Interim ★37	+2	0	Period-end ★38	-1	0	Annual ★75	+1	0
ROE		-	-	-	-	-	-	10.2%	-0.2%	+0.2%
1H Results	1H Results Despite continued weak conditions in the housing market in Japan, recovery trend in global markets, including electronics as well as construction and consumer goods; substantial increase in earnings with operating profit exceeding forecasts (July) mainly on the back of high-performance product sales growth, successful steps to secure margins and control fixed costs, and progress in implementing measures to strengthen profitability in the Housing Business. Both ordinary profit and the bottom line in excess of forecasts (July)									
2H and FY2024 Revised Plan										
Returns to Undertook the repurchase cancellation of a total of 4 million treasury shares (repurchase price ¥8.9 billion); dividends in line with forecasts (luly); plans to pay an annual dividend of ¥75 per share, up ¥1 (interim dividend of ¥37 per share; plans										

Returns to Shareholders Undertook the repurchase cancellation of a total of 4 million treasury shares (repurchase price ¥8.9 billion); dividends in line with forecasts (July); plans to pay an annual dividend of ¥75 per share, up ¥1 (interim dividend of ¥37 per share; plans to pay a period-end dividend of ¥38 per share); plans for a fifteenth consecutive FY of dividend growth

Topic Perovskite Solar Cell Demonstration Project: Selected to participate in the NEDO Green Innovation Fund; accelerating the pace toward commercialization

Results for 1H FY2024

Forex rate	1H	1H	FY2024
	FY2023	FY2024	Initial Plan
In-house	-	¥156/US\$	¥150/US\$
assumptions		¥168/€	¥161/€
Results (Avg. rate for each term)	¥141/US\$ ¥153/€	¥153/US\$ ¥166/€	-

* Export data is subject to in-house assumptions regarding foreign currency exchange rates. A ¥1 depreciation in the value of the yen against the USD has the effect of increasing operating profit by approximately ¥500 million each year at the assumed in-house rate.

Futoshi Kamiwaki

Representative Director Senior Managing Executive Officer Head of Business Strategy Department

Overview of 1H FY2024 Results

- Increase in net sales; substantial increase with operating profit exceeding forecasts (July)
- Ordinary profit in excess of forecasts (July)
- The bottom line in excess of forecasts (July) owing to such factors as the contribution from gain on sales of cross-shareholdings
- Interim dividend of ¥37 per share (up ¥2) in line with forecasts (July)

(JPY billion)	1H FY2023	1H FY2024 ☆ : Record high	Difference	1H FY2024 Forecasts (July)	Difference
Net sales	611.3	★629.1	+17.8	635.7	-6.6
Operating profit	41.2	★48.7	+7.6	44.8	+3.9
Ordinary profit	51.5	48.1	-3.4	46.3	+1.8
Profit attributable to owners of parent	44.5	42.9	-1.5	39.5	+3.4
Dividend per share (JPY)	35	★37	+2	37	0

- Increase in net sales across all segments except Housing. Achieved increases in operating profit across all segments in excess of forecasts (July)
- HPP*: Substantial increases in net sales and operating profit owing to the recovery in demand for electronics as well as construction and consumer goods, high-performance product sales growth, and successful efforts to control fixed costs
- Housing*: Despite a decrease in the number of houses sold, increase in operating profit due to reductions in fixed costs and Stock Business (Renovation/Real Estate) expansion
- UIEP*: Improvements in selling prices and successful efforts to control fixed costs offset the impact of an increase in total costs; increases in both net sales and operating profit
- Medical: Increases in net sales and operating profit on the back of successful efforts to capture diagnostics demand in Japan and overseas and growing sales of infectious disease testing kits in the U.S.
- Other: Progress essentially in line with forecasts (July); breakdown: PV* down ¥0.7 billion, LB* down ¥0.9 billion, BR* down ¥1.1 billion, R&D and other down ¥3.2 billion

	1H FY2023 1H FY2024 Difference ☆ : Record high		1H FY2024 Forecasts (July)		Difference					
(JPY billion)	Net sales	Operating profit	Net sales	Operating profit	Net sales	Operating profit	Net sales	Operating profit	Net sales	Operating profit
HPP	200.3	23.0	★ 221.1	★ 29.9	+20.8	+6.9	223.0	27.2	-1.8	+2.7
Housing	264.8	13.0	253.7	14.6	-11.2	+1.6	255.1	13.5	-1.4	+1.1
UIEP	109.7	8.1	★ 113.4	★8.5	+3.8	+0.4	114.3	8.3	-0.9	+0.2
Medical	43.7	5.1	★ 47.9	★6.0	+4.2	+0.8	49.3	5.4	-1.4	+0.6
Other	3.2	-5.1	3.5	-5.9	+0.3	-0.8	4.1	-5.9	-0.6	0
Eliminations or corporate expenses	-10.3	-2.9	-10.5	-4.2	-0.2	-1.4	-10.1	-3.7	-0.4	-0.5
Total	611.3	41.2	★629.1	★ 48.7	+17.8	+7.6	635.7	44.8	-6.6	+3.9

* HPP: High Performance Plastics Company, Housing: Housing Company, UIEP: Urban Infrastructure & Environmental Products Company

* LB: Stationary Lithium-Ion Batteries Business, BR: Biorefinery Business




Continued increase in 2Q operating profit Group-wide and across all segments

	1Q FY2023		1Q FY2024		2Q FY	2023	2Q FY2024	
(JPY billion)	Net sales	Operating profit	Net sales	Operating profit	Net sales	Operating profit	Net sales	Operating profit
HPP	96.1	9.9	110.6	14.7	104.2	13.0	110.5	15.2
Housing	121.0	4.0	116.2	4.9	143.8	9.0	137.4	9.7
UIEP	51.3	3.4	52.5	3.5	58.4	4.7	60.9	4.9
Medical	20.5	2.0	22.3	2.3	23.2	3.2	25.5	3.6
Other	1.5	-2.3	1.7	-3.0	1.6	-2.8	1.8	-2.9
Eliminations or corporate expenses	-5.0	-1.6	-4.6	-2.2	-5.3	-1.3	-5.9	-2.0
Total	285.4	15.3	298.8	20.2	325.9	25.9	330.2	28.5



Despite continued weak conditions in the housing market in Japan, substantial increase in sales volumes and product mix owing the recovery in global market conditions and high-performance product sales growth; increase in fixed costs, including investment in human capital offset by thoroughgoing efforts to secure margins; results in excess of forecasts (July)




FY2024: Revised 2H and Full FY Plans

Forex rate	2H FY2023	3Q FY2024 Revised Plan	4Q FY2024 Revised Plan	2H FY2024 Revised Plan	FY2024 Initial Plan
In-house assumptions	-	¥149/US\$ ¥163/€	¥140/US\$ ¥163/€	¥145/US\$ ¥163/€	¥150/US\$ ¥161/€
Results (Avg. rate for each term)	¥148/US\$ ¥160/€	-	-	-	-


Number of Automobiles Manufactured (YoY)

2Q trends slightly below forecasts (July); despite falling below assumptions (April) in the 3Q, trends projected to come in line with expectations from the 4Q



Smartphone Shipments (YoY)

2Q trends in line with forecasts (July); while 3Q trends projected to fall below expectations (April), market conditions in the 4Q anticipated to recover to roughly the same level as the previous year



Copyright© SEKISUI CHEMICAL CO., LTD.

Housing • Visitors (YoY)

*Figures in parentheses: 1H forecasts (July) 2H plans (April)


In the 1H, overall visitors exceeded the level recorded in the previous year due to an increase in requests via the WEB; this trend projected to continue in the 2H and beyond

	1H FY23	2H FY23	1H FY24	2H FY24
Overall visitors	97%	100%	105% [105%]	101% [98%]
Via WEB	108%	118%	119% [115%]	110% [95%]
Exhibition visitors	90%	95%	91% [96%]	92% [107%]

New Housing Starts


Continued sluggish demand; FY2024 2H forecasts in line with the previous year

* Timing when demand for each of the UIEP Company's products can be expected to emerge: Four to six months after the start of residential construction



Domestic Naphtha Price Assumptions

2Q FY2024: Trends slightly below forecasts (July) 3Q FY2024 onward: Trends projected to exceed expectations (April)



2H FY2024 Revised Plan by Segment

SEKISUI


- Increases in net sales and operating profit Group-wide and across all segments; in addition to capturing the recovery in market conditions and demand as well as continued high-performance product sales growth, focus on securing margins; contributions from measures to strengthen housing profitability also expected to emerge
- HPP: Market conditions forecast to recover to a certain degree; also focus on securing margins; net sales and operating profit forecast to increase
- Housing: Continue to implement measures to strengthen profitability; net sales and operating profit forecast to increase on the back of Stock (Renovation/Real Estate) and Town and Community Development business expansion
- UIEP: Forecast continued recovery in non-residential market conditions; surge in total costs offset by improvements in selling prices; net sales and operating profit forecast to increase
- Medical: Net sales and operating profit forecast to increase substantially on the back of such factors as successful efforts to capture diagnostics demand in Japan and overseas and growing sales of infectious disease testing kits as well as mainstay pharmaceutical ingredients
- Other: Progress essentially in line with plans (April); breakdown: PV* down ¥1.1 billion, LB down ¥0.3 billion, BR down ¥2.2 billion, R&D and other down ¥3.4 billion

	2H FY2023		2H FY2024 Revised Plan ☆ : Record high		Difference		2H FY2024 Plan (Apr.)		Difference	
(JPY billion)	Net sales	Operating profit	Net sales	Operating profit	Net sales	Operating profit	Net sales	Operating profit	Net sales	Operating profit
HPP	212.6	28.0	★ 223.9	★29.2	+11.3	+1.2	233.3	30.4	-9.4	-1.2
Housing	264.9	14.8	273.0	16.5	+8.1	+1.7	276.0	17.0	-3.0	-0.5
UIEP	125.1	14.1	★ 132.8	★ 15.9	+7.6	+1.8	133.5	15.9	-0.7	0
Medical	48.9	5.8	★55.0	★7.3	+6.0	+1.5	54.2	7.3	+0.8	0
Other	4.1	-5.7	5.3	-7.0	+1.3	-1.3	5.9	-6.9	-0.6	-0.1
Eliminations or corporate expenses	-10.4	-3.7	-10.4	-5.8	0	-2.1	-10.8	-4.5	+0.4	-1.3
Total	645.2	53.2	★ 679.6	★56.3	+34.4	+3.0	692.1	59.2	-12.5	-2.9

2H FY2024 Revised Plan Analysis



Despite continued weak conditions in the housing market in Japan, domestic nonresidential and global market conditions forecast to continue to recover to a certain degree; substantial increase in sales volumes and product mix; focus on securing margins; despite the anticipated impact of foreign exchange losses compared with plans (April), net sales and operating profit forecast to increase with operating profit expected to hit a record high in the 2H



FY2024 Revised Plan by Segment



- Increases in Group-wide net sales and operating profit; the HPP Company to continue driving the Group's performance with the other three segments trending toward a recovery and growth trajectory; upward revision of full FY forecasts for all segments
- Operating profit expected to reach ¥105 billion, further upward revision of ¥3 billion from forecasts (July)

	FY2	023	Revised	FY2024 Revised Plan ☆ : Record high		Difference		2024 sts (July)	Difference	
(JPY billion)	Net sales	Operating profit	Net sales	Operating profit	Net sales	Operating profit	Net sales	Operating profit	Net sales	Operating profit
HPP	412.9	50.9	★ 445.0	★59.1	+32.1	+8.2	452.5	56.7	-7.5	+2.4
Housing	529.7	27.7	526.7	31.1	-3.0	+3.4	536.0	30.0	-9.3	+1.1
UIEP	234.8	22.1	★246.2	★24.4	+11.4	+2.3	245.4	24.0	+0.8	+0.4
Medical	92.6	11.0	★ 102.9	★ 13.3	+10.3	+2.3	103.8	12.6	-0.9	+0.7
Other	7.3	-10.8	8.8	-12.9	+1.5	-2.1	10.1	-12.9	-1.3	0
Eliminations or corporate expenses	-20.7	-6.5	-20.9	-10.0	-0.2	-3.5	-21.1	-8.4	+0.2	-1.6
Total	1,256.5	94.4	* 1,308.7	★ 105.0	+52.2	+10.6	1,326.7	102.0	-18.0	+3.0


FY2024 Revised Plan and Returns to Shareholders



- Increase in net sales; upward revision in operating profit; operating profit projected to hit a record high
- Ordinary profit and the bottom line in line with forecasts (July); the bottom line projected to hit a record high
- Dividend per share in line with forecasts (July); plans to pay an annual dividend of ¥75 per share, up ¥1 per share, for a 15th consecutive period of dividend increase (period-end: ¥38 per share)

(JPY billion)	FY2023	FY2024 Revised Plan ☆ : Record high	Difference	FY2024 Forecasts (July)	Difference
Net sales	1,256.5	★ 1,308.7	+52.2	1,326.7	-18.0
Operating profit	94.4	★105.0	+10.6	102.0	+3.0
Ordinary profit	105.9	102.5	-3.4	102.5	0
Profit attributable to owners of parent	77.9	★78.0	+0.1	78.0	0
Dividend per share (JPY)	74	★75	+1	75	0

Accelerating the shift to growth; target operating profit of ¥105 billion based on the Medium-term Plan



High Performance Plastics Company

Ikusuke Shimizu

Company President

FY2024 1H Results and 2H Revised Plan

- 1H: Increases in net sales and operating profit in excess of forecasts (July) owing to the recovery in mainly semiconductor and other electronics-related as well as construction and consumer goods demand, the growth in sales of high-performance products, and successful efforts to reduce fixed costs; achieved record high operating profit in the 1H. Decision to expand production capacity through investment in one project in the Mobility field and two projects in the Electronics field as a part of the Group's growth strategy
- 2H: Market conditions forecast to recover to a certain degree; plans for increases in net sales and operating profit across all three strategic fields; also focus on securing margins; target record high 2H and full FY operating profit

13.5% 13.2% 13.0% 12.2% 11.6% 11.3% 11.5% 10.1% 10.1% **OP** margin 6.6% 223.9 221.1 O 212.6 200.3 201.5 194.9 188.7 170.8 170.1 (JPY billion) 139.1 29.9 29.2 Ė 28.0 23.0 23.0 Net sales 20.4 19.8 19.3 19.7 Operating 9.2 profit 1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022 1H 2023 2H 2023 1H 2024 2H 2024 **Revised Plan** * Data from FY2022 after portfolio reorganization 1H 2020 2H 2020 1H 2021 2H 2021 1H 2022 2H 2022 1H 2023 2H 2023 1H 2024 2H 2024* 1 USD 107 JPY 105 JPY 110 JPY 115 JPY 134 JPY 135 JPY 141 JPY 148 JPY 153 JPY 145 JPY Forex rate 1 EUR 121 JPY 126 JPY 131 JPY 130 JPY 139 JPY 137 JPY 153 JPY 160 JPY 166 JPY 163 JPY *2H FY2024 Assumptions 2H FY2020 2H 2021 2H FY2023 1H FY2024 Main M&As 1H FY2023 and Started operations Started operations Decision to expand Started operations at a Decision to expand production capacity for interlayer films in Strategic at a new interlayer at a new heat new interlayer film resin production capacity of Investments production line in release materials production line in Europe Thailand, semiconductor polyvinyl acetal resin Europe plant in North


Performance Trends

manufacturing process materials, and


conductive fine particles

America

Recovery in electronics-related as well as construction and consumer goods demand; in addition, firm trends also in the Mobility field; substantial increase in sales volumes and product mix; substantial increases in net sales and operating profit on the back of improvements in margins as well as successful efforts to control fixed costs; results in excess of forecasts (July)



- Trends in demand forecast to remain firm; projecting an increase in net sales mainly on the back of improvements in sales volumes and product mix; improvements in selling prices and cost reductions etc. to offset the impact of soaring raw material prices; projecting an increase in operating profit
- Despite operating profit falling below plans (April) owing to the impact of foreign exchange losses, targeting a record high in the 2H and full FY



HPP Company


Net Sales Trends and KPIs in the Three Strategic Fields

Electronics

Electronics (semiconductor and display materials)

- 1H: Firm smartphone market conditions; in addition to a recovery in semiconductor demand, progress in capturing new orders; substantial growth mainly in the non-LCD field
- 2H: Continue to focus on capturing new orders
- Decision to increase production capacity
 of conductive fine particles

(JPY billion)



Focus on the non-LCD field

Non-LCD field sales ratio 70% 69% 70% 71% 68% 67% 66% 62% Liquid Crystal Net Sales (JPY billion) Non-LCD 16.9 16.8 16.4 15.7 14.8 14.2 13.7 12.6 5.1 5.0 4.8 4.8 4.9 4.8 4.5 4.7 10.9 11.711.8 11.69.8 9.5 9.3 7.9 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q FY23 FY23 FY24 FY24 **FY23** FY23 FY24 FY24

Mobility


 1H: Despite the significant impact of the drop in interlayer film sales volumes for HUD application in China (1H: 99%* in products for HUDs on a sales volume basis), steady growth in N-HPP interlayer film sales volumes

Growth


potential

high-performance interlayer film.

- 2H: Continued growth in N-HPP sales mainly through the acquisition of new models (4Q) (2H: 110%* in products for HUDs on a sales volume basis)
- SEKISUI AEROSPACE CORPORATION: Target a return to profitability in the 2H



High-performance interlayer film sales growth




11 businesses clarified as strengthening the current PF in the Drive 2.0 Medium-term Management Plan.

Industrial


Molding products, sensing

- 1H: Recovery in construction and consumer goods demand in the U.S. and Japan
- 2H: The effect of improvements in selling prices to emerge; continue to focus on sales growth of laborsaving, environmentally friendly products



Labor-saving, environmentally friendly product sales growth

YoY growth rate




* N-HPP: New high-performance products; A generic term for all other HUD, heat insulation, and colored / designed film, excluding sound insulation film from conventional high-performance interlayer films



Masahide Yoshida

Company President


- 1H: Despite a downturn in net sales owing to the decrease in the number of houses sold, increase in operating profit as the effects of measures to strengthen profitability began to emerge as well as Stock Business (Renovation, Real Estate) expansion; operating profit exceeded forecasts (July)
- 2H: Despite the number of houses sold coming in line with the previous year, plans to increase net sales and operating profit on the back of ongoing measures to strengthen profitability as well as Stock Business (Renovation, Real Estate) and Town and Community Development Business expansion



Housing

Company


- Reductions in fixed costs as well as improvements in the product mix and cost reduction, etc. offset the impact of the decrease in the number of houses sold in the Housing Business; secured an increase operating profit; increases in net sales and operating profit in the Renovation Business on the back of order growth underpinned by efforts to strengthen sales personnel
- Decrease in net sales and increase in operating profit across the Housing Company as a whole; operating profit in excess of forecasts (July)



2H FY2024 Revised Plan Analysis



- Continue to implement measures to strengthen profitability; plan to increase operating profit on the back of Stock Business (Renovation, Real Estate) and Town and Community Development Business expansion
- Housing: Strengthen product strategies by area, including urban areas (high-value detached houses, apartment buildings) and regional areas (plan-type products, single-story housing/areas subject to snowfalls, apartment buildings)
- Renovation: Increase orders by upgrading and expanding periodic diagnosis and strengthening proposals; also focus on renovation for non-Heim owners




Copyright© SEKISUI CHEMICAL CO., LTD.

Housing Business

New Housing Orders (YoY)


- 1H: Despite differences between regions, new housing orders roughly in line with forecasts (July)
- 2H: Plans for the mount of orders to come in at 106% YoY owing to improvements in the product mix.



Real Estate Business

Sales of Real Estate

- Increase in the number of dwelling units under management and brokerage growth
- Strengthen the buy-back and resale as well as asset utilization businesses



Copyright© SEKISUI CHEMICAL CO., LTD.


<Amount of Orders and the Number of Buildings by Type of Construction (YoY) >

			FY24 1	Q	2Q	1H	2H		
	sina	Rebuilding	Number%	100%	104%	102%	103%		
	housing		Number%	97%	78%	86%	84%		
	ched		Amount	107%	106%	107%	106%		
	Detached		Number%	100%	99%	100%	100%		
		nortmont buildingo	Amount	105%	111%	108%	104%		
		partment buildings	Number%	94%	105%	100%	101%		
	*	Number : Number of hous	ing units						
	<balance as="" of="" of<br="" orders="">the end of the period> FY24 1H 2H</balance>								
		<balance as="" end="" of="" of<="" orders="" td="" the=""><td>Total amoun</td><td>t 15</td><td>53.5</td><td>16</td><td>0.0</td></balance>	Total amoun	t 15	53.5	16	0.0		
-		the period*>	YoY change	+1	+18.0		3.0		
	*Housing only, excluding renovation (Billions of yen)								


Renovation Business

Renovation Orders


- Order growth on the back of efforts to strengthen the sales system as well as upgrade and expand periodic diagnosis
- Strengthen renovation for non-Heim owners (acquired) a renovation company in Hokkaido)



Measures Aimed at Strengthening Profitability to Ensure Sustainable Growth and Progress



1. Road map to reform the cost structure



2. Strengthen sales promotion

- Expand proposals to high-end customers by strengthening product design
- · Renew exhibition halls, strengthen functions, and promote WEB-based advertising


Urban Infrastructure & Environmental Products Company

Yoshiyuki Hirai

Company President

- UIEP Company
- 1H: Despite the downturn in housing market conditions, non-residential market conditions exhibiting a recovery trend; the increase in total costs offset by improvements in selling prices and successful efforts to control fixed costs; secured an increase in operating profit
- 2H: Continue to focus on addressing the increase in total costs; forecast record-high operating profit in the 2H in line with initial plans (April)
- Target a record high in full FY operating profit (¥24.4 billion)

Games



Started operations at an FFU synthetic wood plant in Europe

COVID-19

Investments


1H FY2024 Results Analysis

The surge in total costs offset by improvements in selling prices and efforts to control fixed costs; secured an increase in operating profit, which exceeded forecasts (July); record-high operating profit in the 1H

- Japan: Substantial progress in expanding sales of prioritized products mainly in the non-residential field
- Overseas: Piping materials for plants struggled owing to the drop in capital investment demand in China and South Korea; firm trends in pipeline renewal and FFU
- Prioritized products: High-value-added products with the potential for market growth and substitutability


UIEP

Company




2H FY2024 Revised Plan Analysis

- While non-residential market conditions are expected to exhibit a certain degree of ongoing recovery, concerns surrounding the shortage of labor at the frontline; slowdown in housing market conditions compared with plans (April); the increase in total costs offset by improvements in selling prices; forecast increases in net sales and operating profit in line with plans (April)
- Japan: Focus on expanding sales of prioritized products while promoting increased acceptance of new prices
- Overseas: Capital investment demand projected to remain weak; focus on securing new CPVC, pipeline renewal, and FFU orders







Copyright© SEKISUI CHEMICAL CO., LTD.

* Including the export of domestic products




Eiichi Takahashi President of SEKISUI MEDICAL CO., LTD

FY2024 1H Results and 2H Revised Plan



- 1H: Increases in net sales and operating income in line with successful efforts to capture diagnostics demand in Japan and overseas and growing sales of infectious disease testing kits in the U.S.; results in excess of forecasts (July) with operating profit hitting a record high
- 2H: Forecasting substantial increases in net sale and operating profit owing to such factors as continued success in capturing diagnostics demand in Japan and overseas as well as growing sales of infectious disease testing kits as well as mainstay pharmaceutical ingredients
- Targeting record high results with full FY net sales exceeding ¥100 billion and operating profit reaching ¥13.3 billion




Strategic Investments XenoTech shares

Start of new facility operations at Iwate Factory

operations at a


GMP-compliant enzyme U.K. factory Despite the impact of a downturn in diagnostics demand in China, operating profit exceeded forecasts (July) owing mainly to growing sales of infectious disease testing kits in the U.S. and successful efforts to control fixed costs; record high operating profit in the 1H



2H FY2024 Revised Plan Analysis



Continue to capture diagnostics demand in Japan and overseas while focusing on expanding sales of infectious disease testing kits as well as blood coagulation devices and reagents in China; work to offset the upswing in development expenditures and fixed costs through increase production; net sales and operating profit forecast to increase substantially; targeting record high operating profit in the 2H






Net sales by Business and Overview of Progress

Diagnostics (Japan)


- 1H: Capture firm diagnostics demand in Japan
- 2H: Continue to capture testing demand focusing on immunology and infectious diseases



Pharmaceutical Sciences (Pharmaceutical and Fine Chemicals, Drug Development Solutions, Enzymes)

Pharmaceutical science (CDMO)

- 1H: Firm trends in the mainstay pharmaceutical ingredients and drug development solutions business
- 2H: Focus on further capturing new orders; establish a CDMO structure and systems at the Group's U.K. factory (operations scheduled to commence in March 2025)




Copyright© SEKISUI CHEMICAL CO., LTD.

Diagnostics (overseas)


Overseas testing system


- 1H: Despite the impact of a drop in diagnostics demand in China, increase in net sales on the back of an upswing in infectious disease testing demand in the U.S.
- 2H: Focus on expanding infectious disease testing kit sales channels in the U.S. as well as sales of blood coagulation devices and reagents in China



Trends in Net Sales of Infectious Disease Testing Kits

- 1H: Efforts to capture influenza diagnostics demand exceeded expectation
- 2H: Work to expand production of FLU/COVID-19 diagnostics kits, focus on expanding sales





Financial Results 1H FY2024

Number of Consolidated Companies

	Mar. 31, 2024	Sep. 30, 2024	Difference
Consolidated subsidiaries	143	144	Increased: 3 Subsidiaries Decreased: 2 Subsidiaries ^{*1}
Affiliates (Equity Method)	6	6	Increased: 0 Subsidiaries Decreased: 0 Subsidiary*2

^{*1} Kofu Sekisui Sangyo Co., Ltd., Toseki Kako Co., Ltd., Shiseki Kako Co., Ltd. ^{*2} PT. Sekisui Indonesia、 Sekisui Chemical India Private Ltd.

Impact of Change in the Number of Consolidated Companies

(JPY billion)	1H FY2024 (YoY)	Difference
Net sales	-0.4	Sanin Sekisui Shoji Co., Ltd. ^{*3} Kofu Sekisui Sangyo Co., Ltd. ^{*4}
Operating profit	+0.1	Toseki Kako Co., Ltd. *4 Shiseki Kako Co., Ltd. *4

*3 Excluded from the scope of consolidation from the 2Q of FY2023

*4 Newly consolidated from the 1Q of FY2024

(JPY billion)		11	H FY2023	1	H FY2024	Diffe	rence	
Net sales			611.3		629.1		+17.8	
Gross profit			188.2		202.8		+14.7	
Gross profit mar	gin		30.8%		32.2%		+1.5%	 Foreign exchange gains: +6.5
Selling, general a expenses	and administrative		147.0		154.1		+7.1	Faraian ayahanga lagagay 4.1
Operating profit			41.2		48.7		+7.6	Foreign exchange losses: -4.1
Share of profit of for using equity r	f entities accounted method		0.4		0.1		-0.3	Gain on sale of investment
Other non-opera expenses	ting profit and		10.0		-0.7		-10.7	securities: +14.5
Ordinary profit			51.5		48.1		-3.4	
Extraordinary pro	ofit		14.2		14.5		+0.2	
Extraordinary los	sses		0.8		1.1		+0.3	
Profit before incor	me taxes		64.9		61.5		-3.5	 Gain on sale of investment
Income taxes, et	c.		19.9		17.5		-2.4	securities: +14.2
Profit attributable interests	to non-controlling		0.6		1.0		+0.4	
Profit attributable	to owners of parent		44.5		42.9		-1.5	
_								
Foreign exchange	1 USD		141 JPY		153 JPY			
(Avg. rate)	1 EUR		153 JPY		166 JPY			

				Inventories (B/S item)	Sep.30 2024	Difference
				Ready-built housing (products)	32.2	-5.8
	Mar. 31, 2024	Sep. 30, 2024	Difference	Prepared land for subdivision housing	67.6	-0.1
(JPY billion)				Land under preparation (work in process)	9.4	-1.0
Cash and deposits	138.6	142.5	+4.0	Housing under construction (work in process)	42.3	+11.5
-	010 5	107.0		Components, other (raw materials)	6.2	-0.1
Trade receivables	213.5	197.8	-15.7	Housing Total	157.8	+4.6
Inventories	298.2	305.8	+7.6	Non-residential total (products, other)	148.0	+3.0
				Inventories Total	305.8	+7.6
Other current assets	35.3	31.4	-3.9			
Property, plant and				 Purchase: +27.5		
equipment	392.5	392.1	-0.4	Depreciation: -21.8	_	
Intangible assets	59.1	60.7	+1.6	Foreign exchange: -5.	3	
intangible assets	55.1	00.7	+1.0			
Investment securities	127.4	115.2	-12.3	 Sale: -17.6		
				Market value: +5.0		
Investments and other assets	58.7	61.6	+2.9	r		
Total assets	1,323.2	1,307.0	-16.2	 Foreign exchange: -1	5.5	
	1,020.2	1,007.0	10.2	Actual basis: -0.7		


Balance Sheets (Liabilities & Net Assets)




(JPY billion)	Mar. 31, 2024	Sep. 30, 2024	Difference	
Non-interest-bearing liabilities	381.6	378.0	-3.6	
Interest-bearing liabilities	120.7	110.1	-10.6	Net profit: +42.9
[Net interest-bearing liabilities]	[-17.8]	[-32.4]	[-14.6]	Dividends paid: -16.5
Total liabilities	502.3	488.1	-14.2	Cancellation of
Share capital etc.	208.6	208.6	0	treasury shares: -7.2
Retained earnings	501.9	521.3	+19.3	
Treasury shares	-48.7	-50.1	-1.4	Cancellation of
Valuation difference on available-for- sale securities	51.2	43.2	-8.0	treasury shares: +7.2 Purchases of
Non-controlling interests	28.6	28.7	+0.1	treasury shares: -8.9
Other net assets	79.2	67.2	-12.0	Foreign currency
Total net assets	820.9	818.9	-2.0	translation
Total liabilities and net assets	1,323.2	1,307.0	-16.2	adjustment: -9.5
Equity-to-asset ratio (%)	59.9%	60.5%	0.6%	
D/E ratio (Net)	-0.02	-0.04	-0.02	



(JPY billion)	1H FY2023	1H FY2024
Cash flows from operating activities	49.3	58.3
Cash flows from investing activities	6.8	-13.9
Cash flows from financing activities	-26.2	-37.8
Net increase in cash and cash equivalents	34.6	4.4
Cash and cash equivalents at end of period	119.8	130.8
Free cash flow =Cash flows from operating activities + Cash flows from investing activities - Dividends paid	42.4	27.0







	De	epreciation	1 ^{*1}		dwill and on ortization		Capita	al expend	tures	EBITDA ^{*3}			
(JPY billion)	1H FY2023	1H FY2024	Differ- ence	1H FY2023	1H FY2024	Differ- ence	1H FY2023	1H FY2024	Differ- ence	1H FY2023	1H FY2024	Differ- ence	
Housing	5.7	5.6	-0.1	0.2	0.2	0	5.2	5.3	+0.1	18.9	20.4	+1.5	
UIEP	4.0	4.2	+0.3	0.3	0.2	-0.1	5.2	3.7	-1.5	12.3	12.9	+0.6	
HPP	10.4	11.0	+0.6	0.6	0.6	0	9.2	12.7	+3.5	34.0	41.5	+7.5	
Medical	2.6	2.9	+0.3	0.3	0.3	+0.1	3.3	2.5	-0.8	8.0	9.2	+1.2	
Other	1.0	0.7	-0.3	-	-	-	0.8	3.3	+2.5	-4.1	-5.2	-1.1	
Eliminations or Corporate expenses	0.5	0.6	+0.1	-	-	-	6.8	4.6	-2.2	-2.4	-3.6	-1.3	
Total	24.2	25.0	+0.8	1.3	1.3	0	30.4	32.1	+1.6	66.7	★75.0	+8.4	

*1 Depreciation does not include amortization of M&A intangible assets

*2 Goodwill and other amortization = Goodwill amortization + Amortization of M&A intangible assets


*3 EBITDA = Operating profit + Depreciation + Goodwill and other amortization



(JPY billion)	FY2023	FY2024 Revised Plan	Difference
Depreciation	50.0	52.3	+2.3
Goodwill and other amortization	2.7	2.7	0
Capital expenditures	60.6	70.0	+9.4
EBITDA	147.1	★ 160.0	+12.9
Research and development expenditure	41.7	44.0	+2.3

Depreciation, Amortization, Capital Expenditures, Research and Development Expenditure

(JPY billion)





This slide presentation contains forward-looking statements. These statements are based on current expectations and beliefs. However, actual results may differ from those expressed or implied due to a number of factors and uncertainties such as changes in the global economy and our business, competition in the market, and regulatory issues.

Note: Figures denominated in units of 100 million JPY are rounded off to the nearest hundred million.

Housing Company Results and Plan



1.	Main data in Housing business		FY2024			FY2023	
		1H	2H Plan	Annual Plan	1H	2H	Annual
	Net sales (JPY billion)	253.7	273.0	526.7	264.8	264.9	529.7
0	Housing	165.2	172.0	337.2	175.3	172.7	348.0
CONSOLIDATED	Renovation	53.8	55.4	109.2	50.9	52.4	103.3
lOS	Other	34.7	45.6	80.3	38.6	39.9	78.4
_ID/	Real estate	27.6	29.5	57.0	27.3	29.2	56.5
TEI	Residential Services	3.4	3.7	7.1	3.6	3.7	7.3
U	Town and Community Development	3.0	11.7	14.6	6.1	5.9	12.0
	Overseas	0.7	0.8	1.5	0.6	0.8	1.4
	1.Number of houses sold (Housing units)	4,315	4,485	8,800	4,675	4,485	9,160
	Detached houses	4,045	4,070	8,115	4,400	4,070	8,470
	Housing/Rebuilding	3,465	3,560	7,025	3,745	3,480	7,225
	Ready-built houses	580	510	1,090	655	590	1,245
	Apartment buildings, other	270	415	685	275	415	690
HTO	2. Main data						
OTHERS	Prices per unit (JPY million) in the detached houses	36.4	-	-	34.8	35.7	35.2
	Prices per tsubo* (JPY thousand) in the detached houses *Tsubo=3.3 Square meter	1,077	-	-	1,010	1,039	1,023
	Floor space (Square meter) in the detached houses	111.6	-	-	113.7	113.3	113.5
	Exhibition places (Units)	400	-	396	430	-	404
	Sales staff (Number of person)	2,355	-	2,217	2,451	-	2,241

Various Performance Data

SEKISUI

Group-wide		FY2	024			FY2	023		FY2022			
■Net Sales (JPY billion)	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
HPP	110.6	110.5	-	-	96.1	104.2	106.0	106.6	99.1	102.4	97.9	97.0
Housing	116.2	137.4	-	-	121.0	143.8	126.7	138.1	115.7	144.5	129.0	148.2
UIEP	52.5	60.9	-	-	51.3	58.4	59.8	65.3	50.1	60.3	59.2	64.7
Medical	22.3	25.5	-	-	20.5	23.2	23.7	25.3	20.6	22.3	22.4	24.4

HPP		FY2	024			FY2	023		FY2022			
■Net Sales by field (JPY billion)	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Electronics	15.7	16.9	-	-	12.6	14.8	14.2	13.7	15.7	12.9	13.1	11.6
Mobility	58.7	58.6	-	-	48.9	55.0	57.4	57.8	43.2	49.3	48.6	50.2
Industrial	26.6	26.5	-	-	24.3	24.9	24.1	25.4	26.7	27.1	25.2	25.4

Electronics field		FY2	024			FY2	023		FY2022			
■Net Sales (JPY billion)	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Liquid Crystal	4.8	5.1	-	-	4.7	4.9	4.8	4.5	5.8	3.7	4.1	4.2
Non-LCD	10.9	11.7	-	-	7.9	9.8	9.5	9.3	9.9	9.2	9.0	7.3
Non-LCD field sales ratio	70%	69%	-	-	62%	68%	66%	67%	63%	71%	69%	63%

Mobility field		FY2	024			FY2	023		FY2022			
■Net Sales (JPY billion)	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
YoY high-performance interlayer film sales volume	112%	100%	-	-	98%	102%	107%	103%	98%	119%	102%	98%

* FY2022 and FY2023: High-performance interlayer film results prior to reclassification; H-HHP interlayer film from FY2024

Copyright© SEKISUI CHEMICAL CO., LTD.

Various Performance Data

SEKISUI

Industrial field	FY2024				FY2023				FY2022			
■Net Sales (JPY billion)	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Labor-saving product	5.9	6.0	-	-	4.9	5.2	4.8	5.6	6.0	5.6	4.8	5.3
Environmentally friendly product	1.9	1.9	-	-	1.7	2.1	2.0	2.2	1.9	1.9	2.1	2.1
Housing	FY2024				FY2023				FY2022			
■Net Sales (JPY billion)	1H		2H		1H		2H		1H		2H	
Housing		7.9		-		6.7		7.9		9.5		11.2
Renovation	5.0		-		4.0		4.2		3.6		4.3	
Other		1.6		-		2.2		2.6		1.7		2.7
UIEP	FY2024			FY2023				FY2022				
■Net Sales (JPY billion)	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Pipe Systems	26.8	31.0	-	-	25.3	29.6	30.1	29.1	25.7	29.8	29.5	28.6
Building and Infrastructures Composite Materials	18.2	20.6	-	-	18.4	20.0	20.5	19.7	17.3	20.8	20.9	20.4
Infrastructure Renovation	5.9	7.4	-	-	5.5	7.0	7.2	14.0	5.0	6.9	5.9	12.7
UIEP	FY2024				FY2023				FY2022			
■Net Sales (JPY billion)	1H		2H		1H		2H		1H		2H	
Prioritized Products (Japan)	22.6		-		19.5		26.5		19.0		24.3	
Overseas		20.2		-		19.5		19.9		22.2		19.5
Medical	FY2024				FY2023				FY2022			
■Net Sales (JPY billion)	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Diagnostics (Japan)	7.6	8.4	-	-	7.6	8.0	8.7	8.0	7.8	7.3	8.1	7.7
Diagnostics (overseas)	11.2	11.8	-	-	9.4	10.0	11.2	12.0	8.9	10.4	10.6	11.2
Pharmaceutical Sciences	3.5	5.4	-	-	3.6	5.2	3.8	5.3	3.9	4.5	3.7	5.5

Copyright© SEKISUI CHEMICAL CO., LTD.

SEKISUI